Cancer Chemotherapy and Pharmacology

, Volume 33, Issue 2, pp 144–148 | Cite as

Effect of pH and moderate hyperthermia on doxorubicin, epirubicin and aclacinomycin A cytotoxicity for Chinese hamster ovary cells

  • Lutz Kleeberger
  • Erwin M. Röttinger
Original Articles Aclacinomycin A, Doxorubicin, Epirubicin, Cytotoxicity, Ovary Cells

Abstract

The influence of extracellular pH on the cytotoxicity of the anthracyclines doxorubicin, epirubicin, and aclacinomycin A was examined at 37° C and 41° C in tissue culture. Chinese hamster ovary (CHO) cells were exposed for a total of 24 h to anthracyclines at doses ranging between 0.12 and 0.69 nmol/ml at pH 7.4,6.7, and 6.4 and at 37° C. Temperature elevation to 41° C was carried out for 3 h after the initiation of the drug treatment. Doxorubicin and epirubicin were about equally cytotoxic in the pH range examined at both temperatures. Aclacinomycin A demonstrated a higher cytotoxicity at pH 7.4 and 37° C only at low doses. At low pH, however, aclacinomycin A was increasingly more effective with increasing dose as compared with doxorubicin and epirubicin. At 41° C and at higher doses aclacinomycin A was even less cytotoxic than doxorubicin or epirubicin. Doxorubicin and epirubicin were less effective at lower pH. However, aclacinomycin A at doses of greater than 0.25 nmol/ml was more cytotoxic at low pH. Moderate hyperthermia did not increase the cytotoxicity of the three drugs at low pH, except for aclacinomycin A at doses of less than 0.25 nmol/ml. At pH 7.4, aclacinomycin A was even less effective at the elevated temperature. At doses of greater than 0.25 nmol/ml, moderate hyperthermia decreased the cytotoxicity of aclacinomycin A at low pH.

Keywords

Cancer Research Tissue Culture Doxorubicin Elevated Temperature Drug Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Born R, Eicholtz-Wirth H (1981) Effect of different physiological conditions on the action of Adriamycin on Chinese hamster cells in vitro. Br J Cancer 44:241Google Scholar
  2. 2.
    Dahl O (1983) Hyperthermic potentiation of doxorubicin and 4′ epidoxorubicin in transplantable neurogenic rat tumor (bt4a) in bd IX rats. Int J Radiat Oncol Biol Phys 9:203Google Scholar
  3. 3.
    Di Marco A, Casazza AM, Dasdia T, Necco A, Pratesi G, Rivolta P, Velcich A, Zaccara A, Zunino F (1977) Changes of activity of daunorubicin, Adriamycin and stereoisomers following the introduction or removal of hydroxyl groups in the amino sugar moiety. Chem-Biol Interact 19:291Google Scholar
  4. 4.
    Engelhardt R (1987) Hyperthermia and drugs. In: Streffer C (ed) Hyperthermia and the therapy of malignant tumors, vol 104. Springer, Berlin Heidelberg New York, p 136Google Scholar
  5. 5.
    Gerweck L (1977) Modification of cell lethality at elevated temperatures. The pH effect. Radiat Res 70:224Google Scholar
  6. 6.
    Groos E, Walker L, Masters JRW (1986) Intravesical, chemotherapy. Studies on the relationship between pH and cytotoxicity. Cancer 58:1199Google Scholar
  7. 7.
    Hahn GM, Braun J, Har-Kedar I (1975) Thermochemotherapy: synergism between hyperthermia (42°–43°) and Adriamycin (or bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci USA 72:937Google Scholar
  8. 8.
    Hahn MH, Shiu EC (1983) Effect of pH and elevated temperatures on the cytotoxicity of some chemotherapeutic agents in Chinese hamster cells in vitro. Cancer Res 43:5789Google Scholar
  9. 9.
    Herman TS, Teicher BA, Jochelson M, Clark J, Svensson G, Coleman CN (1988) Rationale for local use of hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. Int J Hyperthermia 4:143Google Scholar
  10. 10.
    Hetzel FW, Avery K, Chopp M (1989) Hyperthermic “dose” dependent changes in intralesional pH. Int J Radiat Oncol Biol Phys 16:183Google Scholar
  11. 11.
    Hill BT, Whelan RDH (1982) A comparison of the lethal and kinetic effects of doxorubicin and 4′-epi-doxorubicin in vitro. Tumori 68:29Google Scholar
  12. 12.
    Hill BT, Dennis LY, Li X-T, Whelan RD (1985) Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to Adriamycin using a series of mammalian cell lines in vitro. Cancer Chemother Pharmacol 14:194Google Scholar
  13. 13.
    Matsuzawa Y, Oki T, Takeuchi T, Umezawa H (1981) Structure-activity relationships of anthracyclines relative to cytotoxicity and effects on macromolecular synthesis in L1210 leukemia cells. J Antibiot (Tokyo) 34:1596Google Scholar
  14. 14.
    Medonca M, Alpen EL (1983) Extracellular pH and the cell cycle: possible links to radioresistance. In: Broerse JJ, et al (eds) Proceedings of the 7th International Congress on Radiation Research, B7-15. Amsterdam, p1Google Scholar
  15. 15.
    Mizuno S, Amagai M, Ishida A (1980) Synergistic cell killing by antitumor agents and hyperthermia in cultured cells. Jpn J Cancer Res 71:471Google Scholar
  16. 16.
    Morgan JE, Bleehen NM (1981) Response of ETM6 multicellular tumour spheroids to hyperthermia and cytotoxic drugs. Br J Cancer 43:384Google Scholar
  17. 17.
    Ohnoshi T, Ohnuma T, Beranek JT, Holland JF (1985) Combined cytotoxicity effect of hyperthermia and anthracycline antibiotics on human tumor cells. J Natl Cancer Inst 74:275Google Scholar
  18. 18.
    Oki T, Takeuchi T, Oka S, Umezawa H (1981) New anthracycline antibiotic aclacinomycin A. Experimental studies and correlations with clinical trials. In: Carter SK, et al (eds) Recent results in cancer research, vol 76. Springer, Berlin Heidelberg New York, p 21Google Scholar
  19. 19.
    Schwartz HS, Kanter PM (1979) Biochemical parameters of growth inhibition of human leukemia cells by antitumor anthracycline agents. Cancer Treat Rep 63:821Google Scholar
  20. 20.
    Seeber S, Loth H, Crooke ST (1980) Comparative nuclear and cellular incoporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and-resistant Ehrlich ascites in vitro. J Cancer Res Clin Oncol 98:109Google Scholar
  21. 21.
    Shuin T, Moriyama M, Nishimura R, Takai S, Umeda M (1981) Studies on the cytotoxicity, mutagenicity and chromosomal aberration-inducing activity of aclacinomycin A in cultured mammalian cells. Jpn J Cancer Res 72:197Google Scholar
  22. 22.
    Siegfried JM, Burke TG, Tritton TR (1985) Cellular transport of anthracyclines by passive diffusion. Biochem Pharmacol 34:593Google Scholar
  23. 23.
    Sinclair WK, Morton RA (1965) X-ray and ultraviolet sensitivity of synchronized Chinese hamster cells at various stages of the cell cycle. Biophys J 5:1Google Scholar
  24. 24.
    Sund M, Salamon D (1983) BMDP3R-nonlinear regression. In: Regents of UCLA (eds) Revised manual (January 1983) of the October 1983 BMDP version. UCLA Press. Los Angeles, p 290Google Scholar
  25. 25.
    Tanabe M, Tadaoki M, Nakajima Y, Terasima T (1980) Lethal effect of aclacinomycin A on cultured mouse L cells. Jpn J Cancer Res 71:699Google Scholar
  26. 26.
    Thistlewhaite AJ (1985) pH distribution in human tumors. Int J Radiat Oncol Biol Phys 11:1647Google Scholar
  27. 27.
    Tone H, et al (1983) Experimental studies on aclacinomycin. In: Spitzy KH, et al (eds) Proceedings of the 13th, International Congress on Chemotherapy, part 211. Egermann, Vienna, p 1Google Scholar
  28. 28.
    Wheeler RH, Natale RB, Clauw D, Dhafir R (1982) In vitro comparison of the cytotoxic effects of Adriamycin, alcacinomycin, and carminomycin. Proc Am Assoc Cancer Res 23:173Google Scholar
  29. 29.
    Wike-Hooley JL, Haveman J, Reinhold HS (1981) The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 2:343Google Scholar
  30. 30.
    Young RY, Ozols RF, Myers CE (1981) The anthracycline antineoplastic drugs. N Engl J Med 305:139Google Scholar
  31. 31.
    Zenebergh A, Baurain R, Trouet A (1982) Cellular pharmacokinetics of aclacinomycin A in cultured L1210, cells. Comparison with daunorubicin and doxorubicin. Cancer Chemother Pharmacol 8:243Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Lutz Kleeberger
    • 1
  • Erwin M. Röttinger
    • 1
  1. 1.Department of Radiation TherapyUniversity of UlmUlmGermany

Personalised recommendations